Sanofi Stock News

Medtronic's financial results should improve as the economy revives. Sanofi is making progress on several fronts, and there is more on the way.

Sanofi (NASDAQ:SNY ) Q2 2023 Earnings Call Q2 2023 Earnings Call Transcript July 28, 2023 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relations Paul Hudson - Chief Executive

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

French drugmaker Sanofi on Friday increased its guidance for full-year earnings on strong sales of anti-inflammatory treatment Dupixent and promising new drug launches.

While it's usually the smaller enterprises that offer screaming buy opportunities for discerning speculators, sometimes even the best blue-chip stocks to buy don't get the attention they deserve. With

Sanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program.

Sanofi has shown strong growth in 2023, with an 11.9% YoY increase in EPS and a target of $10 billion in sales. The share price has risen nearly 10% YTD. The company's margins are impressive, with gro

Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.

Yahoo Finance Akiko Fujita reports the top stories for Monday July 17, 2023 including Ford cutting the price on the F-150 Lightning, Tesla directors settling a compensation lawsuit, and the FDA approv

RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.

While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.

U.S. Food and Drug Administration said on Monday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th